WAY-151932

Cat. No.:	HY-19381
CAS No.:	220460-92-4
Molecular Formula:	$C_{23}H_{19}ClN_4O$
Molecular Weight:	402.88
Target:	Vasopressin Receptor
Pathway:	GPCR/G Protein
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (496.43 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.4821 mL	12.4106 mL	24.8213 mL
	5 mM	0.4964 mL	2.4821 mL	4.9643 mL
	10 mM	0.2482 mL	1.2411 mL	2.4821 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 5 mg/mL (12.41 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 5 mg/mL (12.41 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 5 mg/mL (12.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

WAY-151932 is a vasopressin V_2-receptor agonist with IC_{50} of 80.3 nM and 778 nM in human-V_2 binding and V_{1a} binding assay.

IC_{50} & Target

IC50: 80.3 nM (human-V2 binding), 778 nM (human-V1a binding)[1]

In Vitro

WAY-151932 (VNA-932) stimulates cAMP formation in LV2 cells expressing the hV_2 receptors in a dose-dependent manner with an EC_{50} of 0.74±0.07 nM[2].

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Oral administration of WAY-151932 (VNA-932) to water-loaded conscious rats produces a dose-dependent decrease in urine volume (ED_{50}=0.14 mg/kg, 2.5% starch in water vehicle) and a corresponding increase in osmolality without altering the urine electrolyte excretion profile[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Molinari AJ, et al. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5796-800.

[2]. Failli AA, et al. Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA